Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
| ▸ | GABRE | P78334 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL27763854 | 0.94 | TSHR (0.46) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Formic Acid SCHEMBL27598762 | 0.92 | CES2 (0.50) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Formic Acid SCHEMBL31335430 | 0.92 | CES2 (0.50) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Formic Acid SCHEMBL28101918 | 0.88 | LMNA (0.50) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Cyclopropane Carboxylic Acid SCHEMBL3108665 | 0.88 | — | — | |
| SCHEMBL17470 | 0.88 | — | — | |
| SCHEMBL3678159 | 0.88 | TSHR (0.55) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10800865 | 0.88 | — | — | |
| Cyclopropane Carboxylic Acid SCHEMBL11243513 | 0.86 | LMNA (0.48) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL8572541 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475673-A1 | CYCLOBUTAN-1,1 -DICARBOXYLATO COMPLEXES OF PLATINUM WITH N6-BENZYLADENINE DERIVATIVES, METHOD OF THEIR PREPARATION AND APPLICATION OF THESE COMPLEXES AS DRUGS IN ANTITUMOUR THERAPY | Univerzita Palackeho (CZ) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029415-A1 | CYCLOBUTAN-1,1 -DICARBOXYLATO COMPLEXES OF PLATINUM WITH N6-BENZYLADENINE DERIVATIVES, METHOD OF THEIR PREPARATION AND APPLICATION OF THESE COMPLEXES AS DRUGS IN ANTITUMOUR THERAPY | UNIVERZITA PALACKEHO (CZ) | 2011-03-17 | — | — | WO | claimed |
| US-4687780-A | ANTICARCINOGENIC AGENTS | JOHNSON MATTHEY PLC (GB) | 1987-08-18 | — | — | US | claimed |
| EP-2475673-A1 | CYCLOBUTAN-1,1 -DICARBOXYLATO COMPLEXES OF PLATINUM WITH N6-BENZYLADENINE DERIVATIVES, METHOD OF THEIR PREPARATION AND APPLICATION OF THESE COMPLEXES AS DRUGS IN ANTITUMOUR THERAPY | Univerzita Palackeho (CZ) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029415-A1 | CYCLOBUTAN-1,1 -DICARBOXYLATO COMPLEXES OF PLATINUM WITH N6-BENZYLADENINE DERIVATIVES, METHOD OF THEIR PREPARATION AND APPLICATION OF THESE COMPLEXES AS DRUGS IN ANTITUMOUR THERAPY | UNIVERZITA PALACKEHO (CZ) | 2011-03-17 | — | — | WO | disclosed |
| US-20110021483-A1 | Platinum (IV) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2011-01-27 | — | — | US | disclosed |
| EP-2170913-A1 | PLATINUM (IV) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155727-A1 | PLATINUM (IV) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-12-24 | — | — | WO | disclosed |
| EP-0586378-B1 | NOVEL PLATINUM(II) COMPLEX AND PROCESSES FOR PREPARING THE SAME | SUNKYONG IND LTD (KR) | 1998-09-23 | — | — | EP | disclosed |
| US-4921984-A | ANTITUMOR AGENTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021483-A1 | Platinum (IV) Complexes | OTC, OAT, SLC25A11 | TSHR 3780/4885GABRP 1103/4885GABRD 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.